MEET THE PATIENT

A NUBEQA® (DAROLUTAMIDE) CASE STUDY



LISTEN & LEARN: FOLLOW ALONG AS DR PARIKH PRESENTS THIS CASE STUDY




Prescribing information and adverse event reporting are available via the QR code or link on the last page. NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease or with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.¹



This promotional material has been organised and funded by Bayer and is intended for UK HCPs only.

PP-NUB-GB-2045 | December 2024



PATIENT CASE NOTES:

Diagnosis: April 2005

Norman presented with obstructive symptoms and underwent a TURP procedure. The MRI scan showed T4 cancer with bladder and rectal involvement and the bone scan showed no metastasis.

Treatment decision


Norman's care was transferred from Urology to Oncology. Due to co-morbidities, including hypertension, heart disease and a pacemaker, he was not offered radiotherapy.

MEET NORMAN[†]:

A retired fork-lift driver who lives with his wife and son. In his free time, Norman likes to spend time with his family.

TIME TO START NUBEQA*

*This patient was part of an extended access programme for NUBEQA



[†]Photo and name are not of actual patient.

This is a real patient case study. This is an individual case, experiences may vary.

ADT, androgen deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; MRI, magnetic resonance imaging; nmCRPC, non-metastatic castrateresistant prostate cancer; PSA, prostate specific antigen; PSA-DT, prostate specific antigen doubling time; QoL, quality of life; TURP, transurethral resection of the prostate.

WHEN PSA CONTINUES TO RISE, CONSIDER NUBEQA®



Case study provided by Dr Omi Parikh

Dr Omi Parikh is a Consultant Clinical Oncologist at the Lancashire Teaching Hospitals NHS Foundation Trust and is Chair of the Lancashire & South Cumbria Urology Network Site Specific Group. Her interests include urological cancers and sarcoma. In the past 15 years, she has co-authored 19 peer reviewed articles and has expertise in prostate cancer, renal cell carcinoma, and chromophobe renal cell carcinoma.

SEPTEMBER 2020

Progressive disease was diagnosed at 91 years old

PSA: 82 ng/mL **PSA-DT:** 4.2 months **ECOG PS:** 1

Not suitable for chemotherapy Non-metastatic disease

Initiated treatment with NUBEQA

Is your patient eligible for NUBEQA?¹

Adult men with nmCRPC who are at high risk of developing metastatic disease may show the following signs:

No metastases detected in recent conventional imaging, pelvic lymph nodes up to 2 cm permissible

Castration-resistant prostate carcinoma (testosterone <1.7 nmol/L PSA increase while on ADT, PSA ≥2 ng/ml)

PSA doubling time of ≤10 months

If your patient meets these criteria, they are at risk of developing metastatic disease.

TREATMENT GOALS:

NORMAN'S

REDUCE SYMPTOMS MAINTAIN PATIENT QoL



PATIENT CASE NOTES:


Norman's treatment plan, follow up and monitoring.

Norman's key therapeutic goal is symptomatic control. Follow up includes monthly PSA surveillance and monitoring of symptoms. No routine imaging is required. *

MARCH 2022



NUBEQA MAY HELP YOU DELIVER ON WHAT'S IMPORTANT TO PEOPLE WITH HIGH-RISK nmCRPC



40 months MFS: more than double the median MFS with NUBEQA + ADT vs ADT + placebo²


NUBEQA + ADT demonstrated 31% reduced risk of death vs placebo + ADT in high-risk nmCRPC

ARAMIS is a multinational, randomised, double-blind, placebo-controlled Phase 3 trial investigating the safety profile and efficacy of darolutamide in patients with nmCRPC[†]

PATIENT CASE NOTES:

For Norman, NUBEQA is well tolerated, and his symptoms have lessened. He has shown improvements in pain and renal function, and no longer experiences problems with haematuria.

IN ARAMIS, NUBEQA + ADT SHOWS A GENERALLY ACCEPTABLE TOLERABILITY PROFILE AND LOW DISCONTINUATION RATE VS $PIACEBO + ADT^{2,3}$



8.9% VS **8.7%** OF PATIENTS DICONTINUED DUE TO AES ON NUBEQA + ADT VS PLACEBO + ADT, RESPECTIVELY^{3,4}

THE CLINICAL BENEFIT OF NUBEQA + ADT HAS BEEN SHOWN TO EXTEND SEVERAL YEARS VS PLACEBO + ADT³

30 OF PATIENTS RECIEVED NUBEQA FOR ≥ 4 YEARS³

This is an individual case, experiences may vary.

ADT, androgen deprivation therapy; AE, adverse event; CI, confidence internal, DB, double-blind; HR, hazard ratio; MFS, metastasis-free survival; nmCRPC, non-metastatic castration-resistant prostate cancer; OL, open-label; OS, overall survival, PSA, prostate specific antigen; ROS, rollover study.

*Radiological imaging may be considered if clinically appropriate for disease progression.

† ARAMIS trial. Men with high-risk nmCRPC. NUBEQA + ADT (n=955) vs. placebo + ADT (n=554). Primary endpoint was MFS.


CASE NOTES:

Since starting NUBEQA, Norman has experienced an improvement in his symptoms and overall QoL. He has no recorded toxicities and had no dose reductions since commencing treatment.

NUBEQA HAS SHOWN LOW RATES OF DISCONTINUATION IN A REAL-WORLD SETTING⁵

The DEAR study: Use of Darolutamide, Enzalutamide and Apalutamide in the Real World for nmCRPC, presented at ASCO GU 2023

The DEAR study was a retrospective, observational chart review study using electronic medical records from the Precision Point Specialty network of US urology practices. The DEAR study was not a head-to-head trial. All patients had nmCRPC, and the primary endpoint was a composite of the time to initial ARi discontinuation or progression to mCRPC⁵.



Median time to discontinuation/progression to mCRPC (95% CI)

NUBEQA	Enzalutamide	Apalutamide
Not reached (30.1, NA)	23.1 (18.2, 26.4)	20.5 (12.3, 27.2)

THE DEAR STUDY⁵

- Enhances our knowledge of nmCRPC management in the real-world setting
- Supports the low discontinuation rate for NUBEQA seen in ARAMIS (rates of discontinuation due to AE: 8.9% in ARAMIS vs. 9.7% in DEAR)









This is an individual case, experiences may vary.

ADT, androgen deprivation therapy; AE, adverse event; ARi, androgen receptor inhibitor; CI, confidence internal, NA, not available; HR, hazard ratio; mCRPC, metastatic castrationresistant prostate cancer; QoL, quality of life; SmPC, summary of product characteristics.

Don't let the learning stop here. Access the latest on prostate cancer and Nubeqa® on our Hub, including podcasts, on demand webinars and other educational resources.

SCAN HERE

HELP HIM LIVE FOR WHAT HE LOVES. THINK NUBEQA¹⁻⁵

MEDIAN METASTASIS-FREE SURVIVAL

22 MONTHS longer MFS vs. placebo + ADT²

DISCONTINUATION RATES

Similar rates of discontinuation of treatment due to adverse events vs. placebo + ADT²

> (Rate of treatment discontinuation: 8.9% vs. 8.7%)^{3,4}

(40.4 months vs. 18.4 months, HR: 0.41; 95% CI: 0.34–0.50; p<0.001)

ADVERSE EVENTS

Incidence of AEs of concern vs. placebo + ADT³

(Fatigue (13.2% vs. 8.3%); Bone fracture (5.5% vs. 3.6%); falls, including accident (5.2% vs. 4.9%); cognitive disorders (2.0% vs. 1.8%); rash (3.1% vs. 1.1%)



Prescribing information and adverse event reporting information for NUBEQA® (darolutamide) is available via the QR code on the right.

Either click <u>here</u> or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.



References: 1. NUBEQA (darolutmaide) SmPC. 2. Fizazi K et al. N Engl J Med. 2019;380(13): 1235–1246. 3. Fizazi K et al. N Engl J Med. 2020;383: 1040–1049. 4. Shore N. et al. ASCO 2023. Abstract #147. 5. George DJ, et al. ASCO GU. 2023. Poster Presentation 332.